HLF transcription factor, PAR bZIP family memberGenealiases: []
Q-omics provides the consensus-scored HLF profile across patient tissues and cancer cell-line models. HLF expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HLF is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, HLF RNA expression shows 25,671 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where HLF shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HLF — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HLF survival associations across molecular data types. HLF RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HLF RNA expression–survival associations across cancer types. High HLF expression shows favorable associations in KIRC, HNSC, MESO, UVM, LUAD and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HLF RNA expression.
This table summarizes HLF tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for HLF. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HLF shows lower tumor expression in HNSC, BLCA, THCA, COAD, LUAD and KICH. The HNSC box plot shows higher HLF RNA expression in normal versus tumor tissue (log2 FC = −2.401, t-test p < 0.001).
This table shows molecular features associated with HLF in patient tissues and cancer cell lines. In patient samples, HLF shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, HLF RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in CNS and BREAST.
